R
Rakesh Popat
Researcher at St Bartholomew's Hospital
Publications - 16
Citations - 843
Rakesh Popat is an academic researcher from St Bartholomew's Hospital. The author has contributed to research in topics: Bortezomib & Multiple myeloma. The author has an hindex of 10, co-authored 16 publications receiving 801 citations. Previous affiliations of Rakesh Popat include University College London Hospitals NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma
Heather Oakervee,Rakesh Popat,Nicola Curry,Patricia Smith,Curly Morris,M. Drake,Samir G. Agrawal,Jim Stec,David P. Schenkein,Dixie Lee Esseltine,Jamie Cavenagh +10 more
TL;DR: PAD was effective, did not prejudice subsequent PBSC collection, and should be further evaluated in prospective randomized trials.
Journal ArticleDOI
A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma.
Rakesh Popat,Torben Plesner,Faith E. Davies,Gordon Cook,Mark Cook,Peter J Elliott,Eric W. Jacobson,Todd Gumbleton,Heather Oakervee,Jamie Cavenagh +9 more
TL;DR: Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells.
Journal ArticleDOI
Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up
Rakesh Popat,Heather Oakervee,Simon Hallam,Nicola Curry,Liz Odeh,Nicola Foot,Dixie-Lee Esseltine,M. Drake,Curly Morris,Jamie Cavenagh +9 more
TL;DR: Toxicity was lower in PAD2; bortezomib dose reduction may help manage toxicities while retaining efficacy and PAD is highly active as front‐line induction in MM.
Journal ArticleDOI
Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
Rakesh Popat,Heather Oakervee,Catherine D. Williams,Mark Cook,Charles Craddock,Supratik Basu,C. R. J. Singer,Stephen Harding,Nicola Foot,Simon Hallam,Liz Odeh,Simon P. Joel,Jamie Cavenagh +12 more
TL;DR: Bortezomib and low‐dose IV melphalan combination therapy is a safe and highly effective regimen for patients with relapsed multiple myeloma and data suggest further investigation of this combination is warranted.
Journal ArticleDOI
Reduced Dose PAD Combination Therapy (PS-341/Bortezomib, Adriamycin and Dexamethasone) for Previously Untreated Patients with Multiple Myeloma.
Rakesh Popat,Heather Oakervee,Nicola Curry,Nicola Foot,Curly Morris,M. Drake,Samir G. Agrawal,Patricia Smith,David P. Schenkein,Dixie-Lee Esseltine,Jamie Cavenagh +10 more
TL;DR: This preliminary data suggests that reduced dose PAD is well tolerated, efficacious (89% ≥ PR) and does not prejudice subsequent PBSC collection, and supports the continued use of dose adjusted bortezomib in PAD if patients develop toxicity.